Humana Inc.
Humana Inc. HUM Peers
See (HUM) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Healthcare Plans Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| HUM | $244.48 | +1.07% | 29.5B | 17.26 | $14.16 | +1.46% |
| UNH | $311.97 | +0.93% | 282.9B | 13.05 | $23.89 | +2.74% |
| ANTM | $482.58 | +2.71% | 114.6B | 18.99 | $25.41 | +1.72% |
| CI | $330.58 | +1.31% | 88.3B | 18.43 | $17.93 | +1.77% |
| ELV | $388.96 | +1.96% | 87.9B | 15.14 | $25.69 | +1.72% |
| CVS | $68.98 | +0.72% | 87.2B | 16.46 | $4.19 | +3.88% |
| CNC | $54.28 | +0.54% | 27B | 8.00 | $6.78 | N/A |
| MOH | $297.90 | +0.29% | 16.1B | 14.37 | $20.71 | N/A |
| OSCR | $21.44 | +5.05% | 5.5B | 53.64 | $0.40 | N/A |
| ALHC | $14.00 | +1.08% | 2.8B | -29.79 | -$0.47 | N/A |
Stock Comparison
HUM vs UNH Comparison
HUM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUM stands at 29.5B. In comparison, UNH has a market cap of 282.9B. Regarding current trading prices, HUM is priced at $244.48, while UNH trades at $311.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUM currently has a P/E ratio of 17.26, whereas UNH's P/E ratio is 13.05. In terms of profitability, HUM's ROE is +0.10%, compared to UNH's ROE of +0.24%. Regarding short-term risk, HUM is less volatile compared to UNH. This indicates potentially lower risk in terms of short-term price fluctuations for HUM.
HUM vs ANTM Comparison
HUM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUM stands at 29.5B. In comparison, ANTM has a market cap of 114.6B. Regarding current trading prices, HUM is priced at $244.48, while ANTM trades at $482.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUM currently has a P/E ratio of 17.26, whereas ANTM's P/E ratio is 18.99. In terms of profitability, HUM's ROE is +0.10%, compared to ANTM's ROE of +0.14%. Regarding short-term risk, HUM is less volatile compared to ANTM. This indicates potentially lower risk in terms of short-term price fluctuations for HUM.
HUM vs CI Comparison
HUM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUM stands at 29.5B. In comparison, CI has a market cap of 88.3B. Regarding current trading prices, HUM is priced at $244.48, while CI trades at $330.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUM currently has a P/E ratio of 17.26, whereas CI's P/E ratio is 18.43. In terms of profitability, HUM's ROE is +0.10%, compared to CI's ROE of +0.12%. Regarding short-term risk, HUM is less volatile compared to CI. This indicates potentially lower risk in terms of short-term price fluctuations for HUM.
HUM vs ELV Comparison
HUM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUM stands at 29.5B. In comparison, ELV has a market cap of 87.9B. Regarding current trading prices, HUM is priced at $244.48, while ELV trades at $388.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUM currently has a P/E ratio of 17.26, whereas ELV's P/E ratio is 15.14. In terms of profitability, HUM's ROE is +0.10%, compared to ELV's ROE of +0.14%. Regarding short-term risk, HUM is less volatile compared to ELV. This indicates potentially lower risk in terms of short-term price fluctuations for HUM.
HUM vs CVS Comparison
HUM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUM stands at 29.5B. In comparison, CVS has a market cap of 87.2B. Regarding current trading prices, HUM is priced at $244.48, while CVS trades at $68.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUM currently has a P/E ratio of 17.26, whereas CVS's P/E ratio is 16.46. In terms of profitability, HUM's ROE is +0.10%, compared to CVS's ROE of +0.07%. Regarding short-term risk, HUM is more volatile compared to CVS. This indicates potentially higher risk in terms of short-term price fluctuations for HUM.
HUM vs CNC Comparison
HUM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUM stands at 29.5B. In comparison, CNC has a market cap of 27B. Regarding current trading prices, HUM is priced at $244.48, while CNC trades at $54.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUM currently has a P/E ratio of 17.26, whereas CNC's P/E ratio is 8.00. In terms of profitability, HUM's ROE is +0.10%, compared to CNC's ROE of +0.13%. Regarding short-term risk, HUM is less volatile compared to CNC. This indicates potentially lower risk in terms of short-term price fluctuations for HUM.
HUM vs MOH Comparison
HUM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUM stands at 29.5B. In comparison, MOH has a market cap of 16.1B. Regarding current trading prices, HUM is priced at $244.48, while MOH trades at $297.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUM currently has a P/E ratio of 17.26, whereas MOH's P/E ratio is 14.37. In terms of profitability, HUM's ROE is +0.10%, compared to MOH's ROE of +0.26%. Regarding short-term risk, HUM is more volatile compared to MOH. This indicates potentially higher risk in terms of short-term price fluctuations for HUM.
HUM vs OSCR Comparison
HUM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUM stands at 29.5B. In comparison, OSCR has a market cap of 5.5B. Regarding current trading prices, HUM is priced at $244.48, while OSCR trades at $21.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUM currently has a P/E ratio of 17.26, whereas OSCR's P/E ratio is 53.64. In terms of profitability, HUM's ROE is +0.10%, compared to OSCR's ROE of +0.11%. Regarding short-term risk, HUM is less volatile compared to OSCR. This indicates potentially lower risk in terms of short-term price fluctuations for HUM.
HUM vs ALHC Comparison
HUM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUM stands at 29.5B. In comparison, ALHC has a market cap of 2.8B. Regarding current trading prices, HUM is priced at $244.48, while ALHC trades at $14.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUM currently has a P/E ratio of 17.26, whereas ALHC's P/E ratio is -29.79. In terms of profitability, HUM's ROE is +0.10%, compared to ALHC's ROE of -0.81%. Regarding short-term risk, HUM is less volatile compared to ALHC. This indicates potentially lower risk in terms of short-term price fluctuations for HUM.
HUM vs CLOV Comparison
HUM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUM stands at 29.5B. In comparison, CLOV has a market cap of 1.4B. Regarding current trading prices, HUM is priced at $244.48, while CLOV trades at $2.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUM currently has a P/E ratio of 17.26, whereas CLOV's P/E ratio is -69.75. In terms of profitability, HUM's ROE is +0.10%, compared to CLOV's ROE of -0.07%. Regarding short-term risk, HUM is less volatile compared to CLOV. This indicates potentially lower risk in terms of short-term price fluctuations for HUM.
HUM vs BHG Comparison
HUM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUM stands at 29.5B. In comparison, BHG has a market cap of 130.5M. Regarding current trading prices, HUM is priced at $244.48, while BHG trades at $16.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUM currently has a P/E ratio of 17.26, whereas BHG's P/E ratio is -0.12. In terms of profitability, HUM's ROE is +0.10%, compared to BHG's ROE of -0.47%. Regarding short-term risk, HUM is less volatile compared to BHG. This indicates potentially lower risk in terms of short-term price fluctuations for HUM.
HUM vs BMGL Comparison
HUM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUM stands at 29.5B. In comparison, BMGL has a market cap of 33.4M. Regarding current trading prices, HUM is priced at $244.48, while BMGL trades at $1.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUM currently has a P/E ratio of 17.26, whereas BMGL's P/E ratio is 19.78. In terms of profitability, HUM's ROE is +0.10%, compared to BMGL's ROE of +0.32%. Regarding short-term risk, HUM is less volatile compared to BMGL. This indicates potentially lower risk in terms of short-term price fluctuations for HUM.
HUM vs MRAI Comparison
HUM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUM stands at 29.5B. In comparison, MRAI has a market cap of 20.1M. Regarding current trading prices, HUM is priced at $244.48, while MRAI trades at $1.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUM currently has a P/E ratio of 17.26, whereas MRAI's P/E ratio is -0.46. In terms of profitability, HUM's ROE is +0.10%, compared to MRAI's ROE of +0.75%. Regarding short-term risk, HUM is more volatile compared to MRAI. This indicates potentially higher risk in terms of short-term price fluctuations for HUM.
HUM vs IVF Comparison
HUM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUM stands at 29.5B. In comparison, IVF has a market cap of 1.9M. Regarding current trading prices, HUM is priced at $244.48, while IVF trades at $0.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUM currently has a P/E ratio of 17.26, whereas IVF's P/E ratio is -0.03. In terms of profitability, HUM's ROE is +0.10%, compared to IVF's ROE of -2.58%. Regarding short-term risk, HUM is less volatile compared to IVF. This indicates potentially lower risk in terms of short-term price fluctuations for HUM.
HUM vs NIVF Comparison
HUM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUM stands at 29.5B. In comparison, NIVF has a market cap of 759.5K. Regarding current trading prices, HUM is priced at $244.48, while NIVF trades at $1.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUM currently has a P/E ratio of 17.26, whereas NIVF's P/E ratio is N/A. In terms of profitability, HUM's ROE is +0.10%, compared to NIVF's ROE of +0.03%. Regarding short-term risk, HUM is less volatile compared to NIVF. This indicates potentially lower risk in terms of short-term price fluctuations for HUM.
HUM vs GTS Comparison
HUM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUM stands at 29.5B. In comparison, GTS has a market cap of 0. Regarding current trading prices, HUM is priced at $244.48, while GTS trades at $35.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUM currently has a P/E ratio of 17.26, whereas GTS's P/E ratio is 10.41. In terms of profitability, HUM's ROE is +0.10%, compared to GTS's ROE of +0.07%. Regarding short-term risk, HUM is more volatile compared to GTS. This indicates potentially higher risk in terms of short-term price fluctuations for HUM.
HUM vs MGLN Comparison
HUM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HUM stands at 29.5B. In comparison, MGLN has a market cap of 0. Regarding current trading prices, HUM is priced at $244.48, while MGLN trades at $94.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HUM currently has a P/E ratio of 17.26, whereas MGLN's P/E ratio is 8.49. In terms of profitability, HUM's ROE is +0.10%, compared to MGLN's ROE of +0.00%. Regarding short-term risk, HUM is more volatile compared to MGLN. This indicates potentially higher risk in terms of short-term price fluctuations for HUM.